Breast cancer models treated with a PI3Kα-specific inhibitor showed reduced TRF1 levels and increased DNA damage, indicating a connection between telomeres, the PI3K pathway and cancer progression [20]. This evidence concerns the gene TERF1 and breast carcinoma.